Commenting on the positive data, Manuel Llobet, Chief Executive Officer of Allergy Therapeutics LON:AGY, said: “Part of our international growth strategy has been to expand our immunotherapy platforms into other
Zeus Capital’s Dr Gary Waanders discusses Allergy Therapeutics plc in this exclusive interview with DirectorsTalk
Allergy Therapeutics Plc (LON:AGY) is the topic of conversation when DirectorsTalk caught up with Dr Gary Waanders the Director of Healthcare Research at Zeus Capital. Gary explains whats driven growth
Allergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in Europe only on
Allergy Therapeutics plc (AGY), the UK-based, specialty pharmaceutical company focused on the development, manufacture and sale of vaccines and other products for the treatment and prevention of allergies, this morning
Commenting on the positive trading update, Manuel Llobet, Chief Executive Officer of Allergy Therapeutics LON:AGY, said: “The Company’s progress continues according to our long-term plans both in gaining market share
Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, today announced that the European Patent Office has granted a broad technology patent relating to the Company’s unique
Manuel Llobet, Chief Executive Officer of Allergy Therapeutics LON:AGY, commented: “It is exciting to announce that our portfolio of adjuvants can be combined to create adjuvant systems that deliver optimised
Zeus Capital’s Dr Gary Waanders discusses Allergy Therapeutics plc in this exclusive interview with DirectorsTalk
Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, has told DirectorsTalk that the Board of Allergy Therapeutics was informed that on 27 September 2016 Nicolas Wykeman,
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
